CoChat

In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy: An Exploratory Study

Open access
van den Brink, Hilde, Kozberg, Mariel G., Makkinejad, Nazanin, Kirsch, John E., Thrippleton, Michael J., van Harten, Thijs W., Voigt, Sabine, Freeze, Whitney M., Van Osch, Matthias J.P., Viswanathan, Anand, van Veluw, Susanne J. · 2025 · Neurology

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 19 of the 27 sources its claims cite were checked for support.

Abstract

Leakage of gadolinium-based contrast agent through the BBB can be measured in vivo in CAA from the leptomeningeal vessels, and findings point to likely leakage from cortical small vessels as well.

Overview

CoChat Summary

## TL;DR

This exploratory prospective MRI study found that gadolinium-based BBB leakage can be measured in vivo in patients with probable CAA without prior lobar ICH. Sulcal CSF enhancement was seen only in CAA (5/14, 36%) and was associated with higher cSS volume, while cortical PS was numerically higher in CAA than controls but not statistically significant.

## Key findings

  • In the primary sample, 14 patients with CAA and 7 non-CAA controls with subjective cognitive complaints or MCI were studied; CAA patients had mean age 67.7 ± 9.0 years and controls 70.1 ± 6.5 years.
  • Focal CSF enhancements were similarly common in CAA and controls: 7/14 (50%) vs 4/7 (57%), p = 0.98; sulcal CSF enhancements were only seen in CAA: 5/14 (36%) vs 0/7 (0%).
  • In patients with CAA, focal and sulcal CSF enhancement counts were associated with higher cSS volume (focal: B = 2.61, p = 0.003; sulcal: B = 1.02, p = 0.02), but not with CMBs.
  • Cortical PS was numerically higher in CAA than controls (5.08 ± 4.02 × 10−4 min−1 vs 1.29 ± 4.08 × 10−4 min−1, p = 0.07; Cohen d = 0.9), but PS was not associated with CMB count or cSS volume (p > 0.67).

## Methods

  • Prospective observational exploratory substudy at Massachusetts General Hospital using participants from a memory-clinic cohort; included 14 patients with probable CAA and 7 non-CAA controls, all without prior intracerebral hemorrhage, scanned between August 2021 and September 2023.
  • MRI protocol at 3T included pre/postcontrast FLAIR for CSF enhancement and 16-minute dynamic contrast-enhanced MRI after IV Dotarem for quantitative PS; optional follow-up FLAIR scans were done at 3, 6, and 24 hours in a subset (8 CAA, 2 controls).
  • Group differences and associations were tested with age-corrected logistic regression, ANCOVA, t tests, and regression models; PS was estimated with the Patlak model.

## Limitations

  • The paper states the main limitation was the small sample size, with low power for PS: 47% power for cortical PS group differences, and 19 participants per group would have been needed for 80% power.
  • The authors note the study is exploratory and could not determine whether BBB leakage predicts disease progression or is an early marker of CAA.
  • Evident from the text: the control group was not a healthy control group but participants with subjective cognitive complaints or MCI, which the authors say may underestimate between-group differences.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000214336

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 An Example of Focal (A and B) and Sulcal (C and D) CSF Enhancement in 2 Participants With Probable CAA CAA = cerebral amyloid angiopathy; FLAIR = fluid-attenuated inversion recovery.
Figure 1 An Example of Focal (A and B) and Sulcal (C and D) CSF Enhancement in 2 Participants With Probable CAA CAA = cerebral amyloid angiopathy; FLAIR = fluid-attenuated inversion recovery.CC BY · PubMed Central
Figure 2 Inflated Cortical Surfaces With Inflated Focal CSF Enhancement (Yellow), Inflated Sulcal CSF Enhancement (Blue), and cSS (Red) Segmentations for Each of the 6 Patients With Probable CAA That Had These Phenomena As exemplified, there is 1 case where 1 focal CSF enhancement directly overlaps an area of cSS. CAA = cerebral amyloid angiopathy; cSS = cortical superficial siderosis.
Figure 2 Inflated Cortical Surfaces With Inflated Focal CSF Enhancement (Yellow), Inflated Sulcal CSF Enhancement (Blue), and cSS (Red) Segmentations for Each of the 6 Patients With Probable CAA That Had These Phenomena As exemplified, there is 1 case where 1 focal CSF enhancement directly overlaps an area of cSS. CAA = cerebral amyloid angiopathy; cSS = cortical superficial siderosis.CC BY · PubMed Central
Figure 3 PS in the Cortex, Total White Matter, and NAWM in Patients With Probable CAA vs Non-CAA Controls CAA = cerebral amyloid angiopathy; NAWM = normal appearing white matter; PS = permeability-surface area product.
Figure 3 PS in the Cortex, Total White Matter, and NAWM in Patients With Probable CAA vs Non-CAA Controls CAA = cerebral amyloid angiopathy; NAWM = normal appearing white matter; PS = permeability-surface area product.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 5 Not checked · 37 Own results and interpretations

22 more claims · 3 with their cited sources checked

Create a free account to see all 56 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 19
  • Probably not a substantial claim. 15
  • Borderline: one of the tests for a substantial claim is unclear. 2

Create a free account to see these claims.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. DOTAREM (Gadoterate Meglumine) Injection for Intravenous Use Initial U.S. Approval. FDA; 2013.

Cited by

See all 11

Metadata

Authors
van den Brink, H., Kozberg, M. G., Makkinejad, N., Kirsch, J. E., Thrippleton, M. J., van Harten, T. W., Voigt, S., Freeze, W. M., Van Osch, M. J. P., Viswanathan, A., & van Veluw, S. J.
Affiliations
  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston;
  • Harvard University (US)
  • Massachusetts General Hospital (US)
  • University of Edinburgh (GB)
  • Leiden University Medical Center (NL)
  • Department of Radiology, Leiden University Medical Center, the Netherlands;
Venue
Neurology
Published
2025-11-25
Volume
105
Issue
10
Pages
e214336-e214336
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W4415937459
Cited by
11
References
36
Citations by year
2026: 10 · 2025: 1
FWCI
6.64
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Edinburgh Research Explorer (University of Edinburgh) (acceptedVersion, cc-by)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • Leiden Repository (Leiden University) (submittedVersion)
Funders
  • Foundation for Cardiovascular Research
  • Fondation Leducq (23CVD03)
  • Universiteit Leiden
  • Universiteit Maastricht
  • Maastricht Universitair Medisch Centrum
  • Leids Universitair Medisch Centrum
  • Alzheimer Nederland
  • National Institutes of Health
  • Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
  • National Institute on Aging (R21AG070363)
  • National Institute of Neurological Disorders and Stroke (R01NS104130)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Clinical Neurology › Cerebrovascular and genetic disorders
Keywords
cerebral amyloid angiopathy, blood-brain barrier disruption, gadolinium-based contrast agents, Dotarem, leptomeningeal vessels, superficial siderosis, cerebral microbleeds, permeability-surface area product, dynamic contrast-enhanced MRI, predictive biomarkers
MeSH terms
Aged, Aged, 80 and over, Blood-Brain Barrier, Brain, Cerebral Hemorrhage, Contrast Media, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Organometallic Compounds, Prospective Studies, Cerebral Amyloid Angiopathy, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy: An Exploratory Study. https://app.cochat.ai/papers/10.1212/wnl.0000000000214336
The paper
van den Brink, H., Kozberg, M. G., Makkinejad, N., Kirsch, J. E., Thrippleton, M. J., van Harten, T. W., Voigt, S., Freeze, W. M., Van Osch, M. J. P., Viswanathan, A., & van Veluw, S. J. (2025). In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy: An Exploratory Study. Neurology. https://doi.org/10.1212/wnl.0000000000214336

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.